Pseudoginsenoside F11

Catalog No.S9199 Batch:S919901

Print

Technical Data

Formula

C42H72O14
Molecular Weight 801.01 CAS No. 69884-00-0
Solubility (25°C)* In vitro DMSO 100 mg/mL (124.84 mM)
 
 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Pseudoginsenoside F11, a natural product found in American ginseng but not in Asian ginseng, is a novel partial PPARγ agonist.
Targets
PPARγ [1]
In vitro Pseudoginsenoside F11 (PF11) promotes the differentiation of 3T3-L1 preadipocytes. It promotes adipogenesis by activating PPARγ[1]. PF11 significantly suppresses the release of ROS and proinflammatory mediators induced by LPS in a microglial cell line N9 including NO, PGE2, IL-1β, IL-6 and TNF-α. Moreover, PF11 inhibits interaction and expression of TLR4 and MyD88 in LPS-activated N9 cells, resulting in an inhibition of the TAK1/IKK/NF-κB signaling pathway. PF11 also inhibited the phosphorylation of Akt and MAPKs induced by LPS in N9 cells[2].
In vivo In in vivo studies, PF11 mitigated the microglial activation and proinflammatory factors expression obviously in both cortex and hippocampus in mice injected intrahippocampally with LPS. PF11 exerts anti-neuroinflammatory effects on LPS-activated microglial cells by inhibiting TLR4-mediated TAK1/IKK/NF-κB, MAPKs and Akt signaling pathways. It may exert therapeutic effects for neurodegenerative disease associated with neuroinflammation[2].

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    3T3-L1 preadipocytes

  • Concentrations

    0, 20, 40 μM

  • Incubation Time

    8 days

  • Method

    3T3-L1 preadipocytes are induced to differentiate with 0, 20, 40 μM Pseudoginsenoside F11 (p-F11) or 0.5 μM rosiglitazone in the absence or presence of 20 μM GW9662 for 8 days.
Animal Study:

[2]
  • Animal Models

    male C57BL/6 mice

  • Dosages

    8 mg/kg

  • Administration

    oral

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.